Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$164.31M$164.31Mderived−1.8% vs Q4 2022 Net Income$1.18M$1.18Mderived−95.4% vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$996,000N/M Operating Cash Flowderived$44,958,000+63.1% Free Cash Flowderived$44,994,000+63.2% Margins · derivedOperating margin-0.6%−21.1 pt vs Q4 2022
Net margin0.7%−14.5 pt vs Q4 2022
ended Dec 31, 2023 · filed Feb 27, 2024 · 58 d after period end